Stockreport

Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease [Seeking Alpha]

Viridian Therapeutics, Inc.  (VRDN) 
PDF VRDN-001 (veligrotug) demonstrates strong efficacy, shorter infusion times, and a superior safety profile, especially regarding hearing-related adverse events, versus T [Read more]